Last $4.51 USD
Change Today +0.09 / 2.04%
Volume 515.2K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 12:26 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$4.47
Previous Close
$4.42
Day High
$4.54
Day Low
$4.39
52 Week High
02/25/14 - $8.00
52 Week Low
04/15/14 - $4.15
Market Cap
325.4M
Average Volume 10 Days
1.2M
EPS TTM
$-0.43
Shares Outstanding
72.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

Related News

No related news articles were found.

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

115 Employees
Last Reported Date: 03/7/14
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $465.0K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $388.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $260.2K
President of Cerus Europe
Total Annual Compensation: $284.8K
Compensation as of Fiscal Year 2012.

cerus corp (CERS) Key Developments

Frank Witney Joins Cerus Corporation's Board of Director and Compensation Committee

Cerus Corporation announced that Dr. Frank Witney, president and chief executive officer of Affymetrix, has joined its board of directors and the compensation committee. Dr. Witney joins the board with over 30 years of experience in the life science industry, specifically focused on corporate strategy and commercialization of products in the life science tools and diagnostics space. Dr. Witney will be filling the board seat recently left vacant by B.J. Cassin upon his retirement from the board on December 31, 2013. Prior to his current position at Affymetrix, Dr. Witney served as president and chief executive officer of Dionex Corp. from April 2009 through its $2.1 billion sale to Thermo Fisher Scientific Inc.

Cerus Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014

Cerus Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, product revenue was $9,232,000 against $10,528,000 for the same period a year ago, the decrease in product revenue was driven by sales declines for both disposable kits and illuminators in several key distributor markets. Loss from operations was $7,806,000 against $3,598,000 for the same period a year ago. Loss from operations before income taxes was $5,807,000 against $1,605,000 for the same period a year ago. Net loss $5,860,000 or $0.10 diluted per share against $1,716,000 or $0.07 diluted per share for the same period a year ago. For the year, product revenue was $39,657,000 against $36,695,000 for the same period a year ago, the year-over-year increase in product revenue was driven primarily by growth in demand for INTERCEPT disposable kits, notably plasma kits, as certain existing platelet customers began purchasing plasma kits during 2013. Loss from operations was $28,299,000 against $17,300,000 for the same period a year ago. Loss from operations before income taxes was $43,119,000 against $15,675,000 for the same period a year ago. Net loss $43,337,000 or $0.64 diluted per share against $15,917,000 or $0.33 diluted per share for the same period a year ago. Net losses were impacted by the mark-to-market adjustments of Cerus' outstanding warrants to fair value, which resulted in non-cash gains of $1.7 million during the fourth quarter of 2013 compared to $2.0 million during the comparable prior year period, and non-cash losses of $15.1 million during the year ended December 31, 2013 compared to non-cash gains of $2.1 million for the comparable period in 2012. For the year 2014, the company anticipates revenue in the range of $38 million to $40 million, reflecting the company's expectation for a temporary negative sales impact during the first half of 2014.

Cerus Corporation, Q4 2013 Earnings Call, Feb 25, 2014

Cerus Corporation, Q4 2013 Earnings Call, Feb 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.51 USD +0.09

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.41 EUR +0.63
InspireMD Inc $2.36 USD -0.032
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.